Pictet Asset Management’s Krystal Biotech KRYS Stock Holding History

Pictet Asset Management’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$40.1M	Sell	107,798 -2,867	-3%	-$857K	0.04%	381
2026 Q1	$28.6M	Sell	110,665 -45,903	-29%	-$12.2M	0.03%	425
2025 Q4	$38.6M	Sell	156,568 -40,336	-20%	-$8.49M	0.04%	377
2025 Q3	$34.8M	Buy	196,904 +66,367	+51%	+$9.93M	0.03%	396
2025 Q2	$17.9M	Buy	130,537 +65,275	+100%	+$9.59M	0.02%	534
2025 Q1	$11.8M	Sell	65,262 -46,827	-42%	-$7.88M	0.01%	617
2024 Q4	$17.6M	Sell	112,089 -3,261	-3%	-$578K	0.02%	542
2024 Q3	$21M	Sell	115,350 -22,083	-16%	-$4.26M	0.02%	487
2024 Q2	$25.2M	Sell	137,433 -5,527	-4%	-$928K	0.03%	408
2024 Q1	$25.4M	Sell	142,960 -49,915	-26%	-$6.93M	0.03%	436
2023 Q4	$23.9M	Sell	192,875 -180,937	-48%	-$20.1M	0.03%	437
2023 Q3	$43.4M	Buy	+373,812	New	+$45.6M	0.05%	309

Other funds holding KRYS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Pictet Asset Management's KRYS Position: Q2 2026 in Review

Pictet Asset Management reduced its Krystal Biotech (KRYS) stake by 2.6% in Q2 2026, selling an estimated $857K and leaving 107,798 shares worth $40.1M. The position accounts for 0.04% of the portfolio, ranked #381.

Pictet Asset Management first reported a position in KRYS in Q3 2023 and has held it in 12 quarters since. The position peaked at $43.4M in Q3 2023. 424 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

Pictet Asset Management held 107,798 shares of Krystal Biotech worth $40.1M as of Q2 2026.
Pictet Asset Management sold 2,867 Krystal Biotech shares in Q2 2026, an estimated $857K.
Krystal Biotech made up 0.04% of Pictet Asset Management's portfolio in Q2 2026, its #381 holding.
Pictet Asset Management first reported a position in Krystal Biotech in Q3 2023 and has held it in 12 quarters since.
Pictet Asset Management's Krystal Biotech position peaked at $43.4M in Q3 2023.
424 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Pictet Asset Management's 13F filing for Q2 2026, filed 30 Jul 2026.